[144] Xenon Pharmaceuticals Inc. SEC Filing

Rhea-AI Filing Summary

Xenon Pharmaceuticals (XENE) filed a Form 144 reporting a proposed sale of 25,000 common shares through Canaccord Genuity Corp. on the NASDAQ with an aggregate market value of $1,004,117. The filer states the shares were acquired and paid for on 10/01/2025 by exercising options issued by the company and paid in cash. The notice lists 77,105,799 shares outstanding and reports no securities sold by the filer in the past three months. Some standard filer identification fields (CIK/Contact) are blank in the provided text.

Positive

• Clear disclosure of class, broker, number of shares, market value, exchange, acquisition method, and payment
• No sales by the filer in the past three months reported, reducing concern about an active disposition pattern

Negative

• Filer identification fields such as CIK and contact information are blank in the provided content, limiting verification

Insights

Financial Analyst

TL;DR: Small insider option exercise and planned sale disclosed; limited market impact given the size relative to outstanding shares.

The filing documents an insider exercising options and proposing to sell 25,000 shares valued at approximately $1.0 million. Versus the 77.1 million shares outstanding, this represents roughly 0.03% of the float, indicating negligible dilution or market impact. The filing clarifies acquisition date and payment method, which helps confirm the transaction is an option exercise rather than a transfer or gift. Absence of recent sales in the prior three months reduces concerns about an ongoing disposition program. Overall, the disclosure is routine and informational for investors tracking insider activity.

Corporate Governance Expert

TL;DR: Proper Rule 144 disclosure of an option exercise and planned sale; filing completeness is mostly adequate though some filer identifiers are missing.

The Form 144 provides the necessary elements: class of securities, broker, number of shares, market value, acquisition method, and payment details, supporting compliance with Rule 144 sale reporting. The representation about lack of undisclosed material information is included as required. However, the excerpt omits explicit filer CIK and contact details shown as blank, which may reflect incomplete source text rather than a filing deficiency. From a governance perspective, the filing appears routine and consistent with transparent insider reporting practices.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Shares	Canaccord Genuity Corp. 1133 Melville St Suite 1200 Vancouver, BC Z4 V6E 4E5	25000	1004117	77105799	10/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	10/01/2025	Exercise of Options	Issuer			25000	10/01/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for XENE report?

The Form 144 reports a proposed sale of 25,000 common shares on NASDAQ through Canaccord Genuity with an aggregate market value of $1,004,117.

How were the 25,000 Xenon shares acquired?

The shares were acquired on 10/01/2025 by exercise of options issued by the company and paid for in cash.

When is the approximate date of sale listed in the filing?

The approximate date of sale is listed as 10/01/2025.

Does the filing show recent sales by the same person?

The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the shares are to be sold.

How material is this sale relative to Xenon's outstanding shares?

The filing shows 77,105,799 shares outstanding; 25,000 shares are about 0.03% of that total, indicating minimal dilution or market impact.